Limited-stage mantle cell lymphoma: Treatment outcomes at the Princess Margaret Hospital

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 261-267

  Bernard, Maryse ^a   Tsang, Richard W ^b   Le, Lisa W ^b   Hodgson, David C ^b   Sun, Alexander ^b   Wells, Woody ^b   Kukreti, Vishal ^c   Kuruvilla, John ^c   Crump, Michael ^c   Gospodarowicz, Mary K ^b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b Department of Radiation Oncology ^*  (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Limited stage; Mantle cell lymphoma; Radiotherapy

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HOSPITAL; HUMAN; MALE; MANTLE CELL LYMPHOMA; MANTLE FIELD RADIOTHERAPY; MULTIPLE CYCLE TREATMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; ONTARIO; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84872009845     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.711828     Document Type: Article

References (31)

1. Banks P, Chan J, Cleary M, et al. Mantle cell lymphoma: Aproposal for unification of morphologic, immunologic and molecular data. Am JSurg Pathol 1992; 16: 637-640.
2. Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). Ann Oncol 1994; 5: 507-511.
3. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: aEuropean MCL intergroup study. Blood 2010; 115: 3215-3223. Romaguera
4. JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97: 586-591.
5. Decaudin D, Bosq J, Munck JN, et al. Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma 1997; 26: 539-550.
6. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385-2387.
7. Fisher RI, Dahlberg S, Nathwani BN, et al. Aclinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): aSouthwest Oncology Group study. Blood 1995; 85: 1075-1082.
8. Ghielmini M, Zucca E. How Itreat mantle cell lymphoma. Blood 2009; 114: 1469-1476.
9. Klapper W, Hoster E, Determann O, et al. Ki-67 as aprognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. JHematop 2009; 2: 103-111.
10. Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14: 1555-1561.
11. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. JClin Oncol 1999; 17: 1244-1253.
12. JaffeES. Lymphoid lesions of the head and neck: amodel of lymphocyte homing and lymphomagenesis. Mod Pathol 2002; 15: 255-263.
13. Hoster E, Dreyling M, Klapper W, et al. Anew prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
14. Dreyling M, Weigert O, Hiddemann W. Current treatment standards and future strategies in mantle cell lymphoma. Ann Oncol 2008; 19 (Suppl 4): iv41-4.
15. Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 398-409.
16. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of aProspective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). JClin Oncol 2005; 23: 1984-1992.
17. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. JClin Oncol 2009; 27: 511-518.
18. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. JClin Oncol 2009; 27: 1209-1213.
19. Geisler CH, Kolstad A, Laurell A, et al. TheMantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive firstline immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530-1533.
20. Katzenberger T, Petzoldt C, Holler S, et al. TheKi67 proliferation index is aquantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107: 3407.
21. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): aclinicopathological study from the European MCL Network. Br JHaematol 2005; 131: 29-38.
22. Rosenwald A, Wright G, Wiestner A, et al. Theproliferation gene expression signature is aquantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
23. ArgatoffLH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: aclinicopathologic study of 80 cases. Blood 1997; 89: 2067-2078.
24. Hartmann E, Fernandez V, Moreno V, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. JClin Oncol 2008; 26: 4966-4972.
25. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of aphase II study of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol 2003; 21: 1740-1745.
26. Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: aretrospective study of 121 cases. Leukemia 1998; 12: 1281-1287.
27. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. Aclinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am JHematol 2000; 64:190-196.
28. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119: 2093-2099.
29. M'Kacher R, Bennaceur A, Farace F, et al. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene 2003; 22: 7905-7912.
30. Rosenbluth BD, Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int JRadiat Oncol Biol Phys 2006; 65: 1185-1191.
31. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: asystematic review and meta-analysis. JNatl Cancer Inst 2007; 99: 706-714.